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Abstract 1 
Objective: To examine whether coenzyme Q10, a potent antioxidant, is associated with 2 
risk of dementia, which has not yet been elucidated. 3 
Approach and Results. We performed a case-control study nested in a 4 
community-based cohort of approximately 6000 Japanese aged 40 to 69 years at 5 
baseline (1984-1994). Serum coenzyme Q10 was measured in 65 incident cases of 6 
disabling dementia with dementia-related behavioral disturbance or cognitive 7 
impairment incident between 1999 and 2004, and in 130 age-, sex- and baseline 8 
year-matched controls. Serum coenzyme Q10 was inversely associated with dementia: 9 
the multivariate odds ratios (95% confidence intervals) were 0.68 (0.26-1.78), 0.92 10 
(0.33-2.56), and 0.23 (0.06-0.86) for individuals with the second, third, and highest 11 
quartiles of coenzyme Q10, respectively, as compared with the lowest quartile (P for 12 
trend =0.05). A similar association was found for the coenzyme Q10/total cholesterol 13 
ratio: the respective ORs were 0.67 (0.25-1.78), 0.73 (0.28-1.92), and 0.21 (0.05-0.90) 14 
(P for trend =0.04). 15 
Conclusions: Serum coenzyme Q10 levels were inversely associated with risk of 16 
disabling dementia. (150 words/150 limit)  17 
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Introduction 1 
Coenzyme Q10 (CoQ10), or ubiquinone, is a vitamin-like substance synthesized by 2 
animal cells. CoQ10 largely exists in the myocardium and plays a role in mitochondrial 3 
energy production. It also has an antioxidant function and is widely consumed as a 4 
supplement in the United States [1]. In addition to the prescription of CoQ10 as an 5 
orphan drug for mitochondrial encephalomyopathy, some evidence exists for a 6 
beneficial effect of CoQ10 on several neurologic diseases such as Parkinson disease [2], 7 
Huntington disease [3], and Friedreich ataxia [4,5] as well as on improved physical 8 
exercise capacity [6] and lowered blood pressure [6,7]. Animal studies have shown a 9 
potential benefit of CoQ10 on cognitive function [8-11]. A randomized controlled trial, 10 
however, has shown that the supplementation of CoQ10 did not influence cerebrospinal 11 
fluid biomarkers in patients with mild-to-moderate Alzheimer disease [12]. Yet, 12 
evidence on this issue is still limited, and no prospective study has been performed on 13 
the preventive effect of CoQ10 on risk of incident dementia in the general population. 14 
 In the present study, we hypothesized that because of its antioxidant effect, 15 
serum level of CoQ10 is inversely associated with disabling dementia. To test this 16 
hypothesis, we conducted a nested case-control study in the Circulatory Risk in 17 
Communities Study (CIRCS), a large community-based cohort study of Japanese 18 
5 
 
population.  1 
 2 
Materials and methods 3 
The CIRCS is an ongoing dynamic community cohort study involving 5 communities in 4 
Japan. Details of the CIRCS protocol have been described elsewhere [13]. In this study, 5 
we included only 1 community, Kyowa, where disabling dementia surveillance is being 6 
carried out, and serum CoQ10 values have been measured. A total of 65 cases of 7 
patients who were diagnosed between 1999 and 2004 as having disabling dementia, 8 
participated in annual health checkups (baseline) at least 5 years before receiving the 9 
dementia diagnosis (ie, between 1984 and 1994), were aged 40 to 69 years at baseline, 10 
and provided sera for storage at baseline were identified. The criteria of disabling 11 
dementia were the same as those of our previous study [14], which also includes the 12 
validation of the criteria and the details of the study protocol. As supplemental analysis, 13 
we further classified the dementia cases into cases with and without history of stroke on 14 
the basis of the systematic stroke registration system described elsewhere [14]. We 15 
excluded individuals aged 70 years or older at baseline, because serum CoQ10 would be 16 
likely affected by the baseline age, and residents aged 70 years and over were not 17 
invited systematically to the baseline examination. One hundred thirty randomly 18 
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selected controls whose age (± 3 years), sex, and follow-up time were matched at a ratio 1 
of 2:1 with the cases were also identified from the risk set. Venous blood was collected 2 
at baseline, and sera were prepared from the blood samples as soon as possible after the 3 
blood collection at the checkup sites. The serum samples were collected in 0.3-mL tubes 4 
and stored at −80°C until measurement in 2005. Serum CoQ10 was measured using 5 
high-performance liquid chromatography (HPLC) at the Public Health Institute of 6 
Kochi Prefecture with modification of the reported methods [15]. Briefly, a 10-μL 7 
serum sample was pretreated with 380 μL of 2-propanol. After centrifugation at 7000 g 8 
for 5 minutes, 10 μL of supernatant was applied to the HPLC system (L-7000 series; 9 
Hitachi High-Technologies Corporation, Tokyo, Japan) using a SUPELCOSIL LC-8 10 
HPLC Column (Sigma-Aldrich Japan, Tokyo, Japan), an RC-10 reduction column 11 
(Shiseido Company, Tokyo, Japan), and an electrochemical detector (SI-2; Shiseido 12 
Company). The oxidation potential for the electrochemical detector was 600 mV. The 13 
mobile phase consisted of 50 mmol/L sodium perchlorate in methanol/2-propanol 14 
(100/10, v/v) with a flow rate of 1 mL/min. Serum total cholesterol was measured at 15 
baseline using the Liebermann-Burchard direct method at the Osaka Medical Center for 16 
Cancer and Cardiovascular Disease, an international member of the US National 17 
Cholesterol Reference Method Laboratory Network (CRMLN) [16]. 18 
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For statistical analyses, we conducted conditional logistic analyses using SAS 1 
9.1.3. Service Pack 4 (SAS Institute, Cary, NC, USA) with adjustments for body mass 2 
index, smoking status, alcohol consumption, diastolic blood pressure, total cholesterol, 3 
diabetes mellitus, and use of medication for hypertension or hypercholesterolemia. 4 
Since CoQ10 and total cholesterol were strongly correlated (Spearman r=0.34), we also 5 
examined the association of the CoQ10/total cholesterol ratio with risk of disabling 6 
dementia. All probability values for the statistical tests were 2-tailed, and probability 7 
values below 0.05 were considered significant. Informed consent was obtained from 8 
community leaders and, verbally, from individual participants according to the 9 
guidelines of the Council for International Organizations of Medical Science [17]. The 10 
study was approved by the institutional review boards of the Osaka Center for Cancer 11 
and Cardiovascular Disease Prevention and of the University of Tsukuba. 12 
 13 
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Results 1 
As shown in Table 1, the baseline characteristics did not differ materially between the 2 
cases and the non-cases, although diastolic blood pressure levels tended to be higher, 3 
and prevalence of cholesterol-lowering medication use, lower for cases than for 4 
non-cases. 5 
 Serum coenzyme Q10 was inversely associated with risk of incident dementia 6 
(Table 2). The multivariate odds ratios and 95% confidence intervals were 0.68 7 
(0.26-1.78), 0.92 (0.33-2.56), and 0.23 (0.06-0.86), for individuals with the second, 8 
third, and highest quartiles of CoQ10, respectively, compared with the lowest quartile 9 
(P for trend =0.05). A similar association was observed for the CoQ10/total cholesterol 10 
ratio. The respective odds ratios were 0.67 (0.25-1.78), 0.73 (0.28-1.92), and 0.21 11 
(0.05-0.90) (P for trend =0.04). 12 
 As supplemental analysis, we stratified dementia cases into those with history 13 
of stroke and those without it. Although the number of cases was limited, the 14 
associations were stronger for dementia without stroke for both serum CoQ10 and the 15 
CoQ10/total cholesterol ratio. The unadjusted odds ratios and 95% confidence intervals 16 
of dementia without stroke were 1.18 (0.37-3.75), 0.50 (0.15-1.70), and 0.46 (0.12-1.74) 17 
for individuals with the second, third, and highest quartiles of CoQ10 (p for trend 18 
9 
 
=0.13), and were 0.47 (0.15-1.48), 0.34 (0.11-1.09), and 0.24 (0.06-0.98) for respective 1 
quartiles of CoQ10/total cholesterol ratio (p for trend =0.04). The corresponding odds 2 
ratios and 95% confidence intervals of dementia with stroke were 0.82 (0.26-2.57), 2.24 3 
(0.63-7.96) and 0.35 (0.06-2.05) according to quartiles of CoQ10 (p for trend =0.45), 4 
and were 1.68 (0.45-6.29), 2.05 (0.51-8.30) and 0.43 (0.06-2.97) according to quartiles 5 
of CoQ10/total cholesterol ratio (p for trend =0.43). 6 
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Discussion 1 
We found a strong inverse association between serum CoQ10 concentration and risk of 2 
disabling dementia in the Japanese population. To date, this is the first prospective study 3 
to examine the association between CoQ10 and incident dementia in a general setting.  4 
 Several animal studies have shown that CoQ10 may have a beneficial effect on 5 
dementia progression. In transgenic mice, dietary supplementation with CoQ10 reduced 6 
brain oxidative stress and deposition of amyloid plaque or amyloid-β and improved 7 
behavioral performance [11]. Rats with damaged hippocampi and cerebral cortices 8 
showed an adverse alteration in the markers of oxidative damage, but with 9 
supplementation with CoQ10, this alteration was reversed [8]. Thus, CoQ10 has been 10 
considered a promising treatment for Alzheimer disease. However, a recent randomized 11 
control trial of patients with mild-to-moderate Alzheimer disease did not show that 12 
antioxidant treatment, including supplementation with high-dose CoQ10, improved the 13 
indices of markers of oxidative stress or of neurodegeneration in the cerebrospinal fluid 14 
[12]. Although this finding warrants confirmation by replication studies, when it is 15 
taken together with the findings of the present study, we assume that CoQ10 could have 16 
a more prominent impact on prevention, rather than on treatment, of dementia. 17 
 The limitations of this study include (1) the relatively small number of cases, 18 
although the associations were strong enough to be detected; (2) the diagnoses of 19 
11 
 
disabling dementia conducted by attending physicians, although such diagnosis by 1 
attending physicians was previously validated [14]; and (3) the use of long-stored sera, 2 
although a previous study showed that the plasma CoQ10 value was unchanged after 3 
being deep-frozen and stored for 3 years [18]. When we excluded the serum samples 4 
collected before 1989 (23 cases and 46 matched controls excluded), the results were 5 
similar (not shown). Fourth limitation is that we did not classify dementia into 6 
Alzheimer type and vascular type. Instead, we have information on dementia with and 7 
without history of stroke. The associations seemed stronger for dementia without history 8 
of stroke, which needs to be confirmed by further studies. Last, we did not survey the 9 
dementia at baseline. However, we constructed the baseline at least 5 years prior to the 10 
beginning of dementia survey, so the possibility of reverse causation may be small. 11 
 The inverse association between serum CoQ10 levels and incident dementia 12 
did not directly assure that dietary intake of CoQ10 would prevent dementia. 13 
Furthermore, CoQ10 supplements were not generally available in Japan at the era of the 14 
baseline period (1984-1994). The impact of dietary or supplementary intake of CoQ10 15 
was not tested in the present study, which must be examined by a randomized control 16 
trial in the future. 17 
 In conclusion, the serum level of CoQ10 was inversely associated with 18 
12 
 
disabling dementia in this Japanese general population, which suggests that higher 1 
serum CoQ10 levels may have a beneficial effect on prevention of dementia. 2 
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Table 1. Baseline characteristics of dementia cases and non-cases, CIRCS aged 40-69 years.
Dementia cases Non-cases p  for difference
Number 65 130
Age, y 64.5 64.1 0.64
Male gender, % 34 34 1.00
Body mass index, kg/m2 24.3 24.1 0.77
Current smokers, % 26 22 0.47
Current drinkers, % 28 28 1.00
Systolic blood pressure, mmHg 137 136 0.43
Diastolic blood pressure, mmHg 81 79 0.08
Antihypertensive medication, % 28 33 0.45
Diabetes mellitus, % 14 7 0.12
Serum total cholesterol, mg/dL 205 201 0.53
Cholesterol-lowering medication, % 3 10 0.09
Serum coenzyme Q10*, nmol/L 731 762 0.32
Coenzyme Q10/total cholesterol ratio*, 10-6 138.5 151.4 0.15
*Median values and p values for differences tested by the Wilcoxon rank sum test.
Q1 Q2 Q3 Q4 Trend p
228-558 559-765 766-1015 1016-2353
Median, nmol/L 459 635 850 1253
Number of cases 18 20 18 9
Number of non-cases 32 33 32 33
Matched OR (95%CI)* 1.0 1.03 (0.47-2.29) 0.94 (0.41-2.14) 0.43 (0.16-1.19) 0.10
Multivariable OR (95%CI)‡ 1.0 0.68 (0.26-1.78) 0.92 (0.33-2.56) 0.23 (0.06-0.86) 0.05
Q1 Q2 Q3 Q4 Trend p
54.1- 107.6-151.3 151.4-203.6 203.7-489.1
Median, 10-6 91.2 127.3 173.6 230.7
Number of cases 21 19 17 8
Number of non-cases 32 33 33 32
Matched OR (95%CI)* 1.0 0.80 (0.35-1.81) 0.72 (0.31-1.67) 0.28 (0.09-0.84) 0.02
Multivariable OR (95%CI)† 1.0 0.67 (0.25-1.78) 0.73 (0.28-1.92) 0.21 (0.05-0.90) 0.04
‡Further includes serum total cholesterol.
Total disabling dementia
*Matched with age (±3 years), sex and baseline-year
†Multivariable model further includes body mass index, smoking status, alcohol consumption, diastolic blood
pressure, diabetes mellitus and medication of hypertension and hypercholesterolemia.
Table 2. Age and sex-matched and multivariate adjusted conditional odds ratios and 95% confidence intervals of
incident dementia according to quartiles of serum coenzyme Q10 and coenzyme Q10/total cholesterol ratio.
Men and Women
Quartiles of serum coenzyme Q10 (nmol/L)
Total disabling dementia
Quartiles of serum coenzyme Q10/total cholesterol ratio (10-6)
